PD1-HM501B-100μg / 询价
PD1-HM501B-500μg / 询价
PD1-HM501B-500μgx2 / 询价
-
关联产品
Biotinylated Human PD-L1/B7-H1 Protein
Cynomolgus/Rhesus macaque PD-L1/B7-H1 Protein
Cynomolgus PD-L1/B7-H1 Protein
Biotinylated Cynomolgus/Rhesus macaque PD-L1/B7-H1 Protein (Primary Amine Labeling)
Biotinylated Mouse PD-L1/B7-H1 Protein (Primary Amine Labeling)
- 客服电话
- 技术支持
Biotinylated Human PD-1/PDCD1 Protein
Recombinant Biotinylated Human PD-1/PDCD1 Protein is expressed from HEK293 with hFc tag and Avi tag at the C-Terminus. It contains Leu25-Gln167.[Accession | Q15116-1]
The protein has a predicted MW of 44.7 kDa. Due to glycosylation, the protein migrates to 65-72 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human PD-1 on Tris-Bis PAGE under reduced. The purity is greater than 95%.
The purity of Biotinylated Human PD-1 is greater than 95% as determined by SEC-HPLC.
Immobilized Human PD-L1, mFc tag at 2μg/ml (100μl/Well). Dose response curve for Biotinylated Human PD-1, hFc tag with the EC50 of 0.23μg/ml determined by ELISA.
Programmed cell death protein 1, also known as PD-1 and CD279 , is a protein found on the surface of cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity.
PDCD1; PD1; CD279; SLEB2; PD-1
(1)Blank C , Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion[J]. Cancer Immunology Immunotherapy, 2007, 56(5):739-745.
